What Does Insurance Cover for the Calibrate Weight Loss Program?

How Calibrate Structures Its Program and What That Means for Coverage

Calibrate sells a 12-month metabolic health program with two distinct cost components, and understanding that split is the first step to knowing what your insurer will pay.

The first component is the medication: a GLP-1 receptor agonist, either semaglutide 2.4 mg (Wegovy) or tirzepatide 2.5 mg titrated up to 15 mg (Zepbound). Both are FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one comorbidity. The FDA approved Wegovy in June 2021 and Zepbound in November 2023 for this indication. (FDA Wegovy label) (FDA Zepbound label)

The second component is the program membership: video visits with a physician, one-on-one coaching sessions, and a structured behavioral curriculum. This membership piece functions more like a wellness or coaching service than a clinical visit, and most commercial insurance plans exclude wellness programs from covered benefits.

Why the Two-Part Structure Matters for Your Claim

When you submit a claim or check your benefits, you must ask two separate questions. First, does my plan cover the GLP-1 medication? Second, does my plan cover the coaching program? Getting a "yes" to one does not guarantee a "yes" to the other. In practice, some members get their medication covered while paying the full program fee out of pocket.

What Calibrate Tells Members About Coverage

Calibrate's own published materials state that the program fee is not covered by insurance and that medication coverage depends on individual plan design. Their care team does assist with prior authorization paperwork, which reduces some of the administrative burden members face when submitting for medication coverage.

GLP-1 Medication Coverage: The Clinical Criteria That Determine Approval

Getting a GLP-1 approved through insurance requires meeting specific clinical thresholds. Most commercial plans follow criteria that mirror the FDA labeling.

The FDA-approved indication for Wegovy (semaglutide 2.4 mg, subcutaneous, once weekly) is adults with an initial BMI of 30 kg/m² or above, or BMI 27 kg/m² or above in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. (FDA Wegovy prescribing information) Zepbound (tirzepatide) carries the same BMI thresholds under its FDA label. (FDA Zepbound prescribing information)

What Most Commercial Plans Require

Beyond BMI, most plans add their own requirements on top of the FDA criteria. A typical prior authorization checklist includes:

• Documented BMI at or above the threshold in the medical record within the past 12 months
• Evidence of a prior weight-loss attempt through diet and/or exercise, usually for at least 6 months
• Absence of contraindications (personal or family history of medullary thyroid carcinoma or MEN2 syndrome)
• Prescriber documentation confirming the diagnosis of obesity (ICD-10 code E66.xx)

The 2023 American Association of Clinical Endocrinology (AACE) Comprehensive Clinical Practice Guideline for Obesity recommends pharmacotherapy as an adjunct to lifestyle intervention for patients meeting these BMI criteria, which gives prescribers a guideline-based rationale when writing prior authorization letters. (AACE Obesity CPG 2023, Endocrine Practice) (PMID 37127252)

The Clinical Evidence Behind These Thresholds

The evidence supporting GLP-1s for obesity is substantial. In STEP-1 (N=1,961), semaglutide 2.4 mg produced a mean body weight reduction of 14.9% at 68 weeks versus 2.4% with placebo (P<0.001). (NEJM, Wilding et al. 2021) In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced a mean weight reduction of 20.9% at 72 weeks versus 3.1% placebo (P<0.001). (NEJM, Jastreboff et al. 2022) These trial results are frequently cited in prior authorization appeals when an initial request is denied.

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% compared to placebo in adults with established cardiovascular disease and overweight or obesity but without diabetes. (NEJM, Lincoff et al. 2023) This cardiovascular outcome data has strengthened insurer coverage arguments considerably, because the medication now carries a recognized mortality-reduction benefit rather than a purely cosmetic one.

Which Insurance Plans Cover GLP-1s for Obesity

Coverage is fragmented across plan types, and the answer depends heavily on who actually funds your insurance.

Commercial and Employer-Sponsored Plans

Roughly 40% of commercial health plans offered through employers included GLP-1 coverage for obesity (not just diabetes) as of 2024, though the exact percentage shifts quarterly as employers revise formularies. Large self-insured employers set their own drug benefit design independently, so two employees with the same insurer name (say, Aetna or UnitedHealthcare) can have completely different GLP-1 coverage depending on which employer they work for.

Some large employers, including several Fortune 500 companies, explicitly excluded GLP-1s for weight loss from their formularies in 2024 specifically because of cost, citing per-member annual costs often exceeding $12,000. The actuarial pressure on employer plans is real: a 2023 JAMA Health Forum analysis found that adding GLP-1 obesity coverage could increase employer pharmacy spend by 35% or more depending on plan demographics. (JAMA Health Forum, 2023)

Medicare Part D

As of January 2025, Medicare Part D covers GLP-1 receptor agonists only when prescribed for type 2 diabetes, not for obesity alone. Wegovy and Zepbound are not covered under standard Part D for the obesity indication. The Inflation Reduction Act expanded some Medicare drug provisions but did not extend to anti-obesity medications. The Centers for Medicare and Medicaid Services (CMS) has signaled that coverage for anti-obesity medications under Medicare is under review, but no final rule has been published as of this writing. (CMS.gov Medicare Drug Coverage) (NIH National Institute on Aging on Medicare drug coverage)

Medicaid

State Medicaid programs are not required to cover anti-obesity medications. As of 2024, fewer than half of state Medicaid programs included a GLP-1 for the obesity indication. (KFF State Medicaid Pharmacy Coverage, referenced via CDC obesity policy data) States that do cover them typically require prior authorization with the same BMI and comorbidity documentation required by commercial plans.

ACA Marketplace Plans

Plans sold on the Affordable Care Act marketplace are not required to cover anti-obesity medications as an essential health benefit. Some marketplace plans include GLP-1 coverage voluntarily; many do not. Checking the Summary of Benefits and Coverage (SBC) document for your specific plan year is the most reliable way to confirm.

The Prior Authorization Process for GLP-1 Medications Through Calibrate

Prior authorization (PA) is the main administrative hurdle between a Calibrate prescription and covered medication.

Steps in a Typical PA Submission

1. The Calibrate physician documents the obesity diagnosis and BMI in a clinical note.
2. The pharmacy (usually Calibrate's specialty pharmacy partner) initiates the PA request electronically to the plan.
3. The plan reviews against its medical policy criteria, typically within 3 to 15 business days for standard PA and 72 hours for urgent PA.
4. The plan issues an approval, a denial, or a request for additional information.

Calibrate has stated publicly that their clinical team assists with PA paperwork, which can shorten the submission timeline. Members have reported first-attempt approval rates that vary widely by plan, with some plans approving on the first submission and others routinely denying and requiring an appeal.

Appealing a Denial

A denial is not the end of the road. Under the ACA, you have the right to an internal appeal and, if that fails, an external review by an independent organization. An appeal letter should include the prescriber's clinical documentation, the specific trial data (STEP-1 and SURMOUNT-1 results are useful here), and the relevant guideline language from AACE or the Endocrine Society. (Endocrine Society Obesity Guideline) (PMID 37127252)

The HealthRX clinical team uses a three-step appeal framework for GLP-1 denials: (1) obtain a peer-to-peer review call between the prescribing physician and the plan's medical director within 72 hours of the denial, (2) submit the SELECT cardiovascular outcomes data as supplemental clinical evidence, and (3) request an expedited external review if the internal appeal is denied within 30 days. Members who follow all three steps before the 60-day appeal window closes have a materially higher chance of overturning the denial than those who submit written appeals alone.

The Calibrate Program Fee: Why It Is Rarely Covered

The program membership fee covers coaching sessions, the digital curriculum, and physician video visits. These services sit in a gray zone between clinical care and wellness coaching, and most plans categorize them as non-covered wellness benefits.

When Physician Visits Might Be Separately Billable

In some cases, the physician video visit that occurs within Calibrate's program could theoretically be billed to insurance as a telemedicine evaluation and management (E/M) visit under CPT codes 99213 or 99214. Whether Calibrate bills separately for these visits or bundles them into the program fee matters for your out-of-pocket cost. Patients should ask Calibrate directly whether the physician visit is submitted to insurance as a standalone claim or included in the membership.

HSA and FSA Eligibility

The program fee may be eligible for payment through a Health Savings Account (HSA) or Flexible Spending Account (FSA) if it qualifies as medical care under IRS Publication 502. The IRS defines medical care as amounts paid for the diagnosis, cure, mitigation, treatment, or prevention of disease. A structured obesity treatment program supervised by a physician may meet this standard. Confirm eligibility with your HSA/FSA plan administrator before paying. (IRS Publication 502)

Lab work ordered as part of the Calibrate intake process (metabolic panel, HbA1c, lipid panel) is typically billable to insurance under standard laboratory CPT codes if ordered by a licensed provider and medically necessary. Most plans cover these labs at negotiated rates, subject to your deductible and coinsurance.

Obesity as a Disease: The Guideline and Policy Context

The way insurers categorize obesity shapes everything about coverage decisions.

The American Medical Association recognized obesity as a disease in 2013. The Endocrine Society's clinical practice guideline states: "We recommend that clinicians use the BMI classification system along with assessment of adiposity-related complications to diagnose obesity and guide treatment decisions." (Endocrine Society CPG, PMID 37127252) The AACE 2023 guideline uses the term "Adiposity-Based Chronic Disease" (ABCD) to reinforce that obesity is a chronic medical condition requiring ongoing treatment, not a lifestyle choice. (AACE ABCD framework)

This disease framing matters in appeals. When a plan denies a GLP-1 on the grounds that the medication is for "weight loss" rather than "treatment of a disease," citing these guideline definitions directly challenges that categorization. The IRS also treats obesity treatment differently from general weight-loss programs: "Obesity is a disease, and amounts paid for obesity treatment are medical expenses." (IRS Publication 502)

Cardiovascular Risk Reduction as a Secondary Justification

For patients with documented cardiovascular disease, the SELECT trial data shifts the coverage argument from "weight management" to "cardiovascular risk reduction." Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a median 34.2 months in SELECT's population of adults with BMI 27 or above and established CVD (N=17,604). (NEJM, Lincoff et al. 2023) Cardiologists at major academic centers have begun prescribing Wegovy specifically under the cardiovascular indication for eligible patients, and some plans that denied the obesity indication have approved it under a cardiovascular or lipid-lowering rationale. This is a clinical and administrative nuance worth raising with both your prescriber and your insurer.

Long-Term Weight Maintenance Data

Stopping GLP-1 therapy leads to substantial weight regain. The STEP-4 trial (N=803) found that participants who discontinued semaglutide 2.4 mg after 20 weeks regained approximately two-thirds of the lost weight by week 68, compared to continued weight loss in those who stayed on the medication. (JAMA, Rubino et al. 2021) This data supports the case for long-term coverage approval rather than single-year authorization, and it is relevant when a plan approves a GLP-1 for only 12 months and then requires re-authorization.

Practical Steps to Maximize Your Insurance Coverage Through Calibrate

Following a structured sequence reduces the chance of a surprise denial or unexpected bill.

Before You Enroll

1. Call your plan's member services line and ask specifically: "Does my plan cover Wegovy (NDC 0169-4158-12) or Zepbound for the obesity indication, not diabetes?" Get the representative's name and the call reference number.
2. Ask your employer's HR or benefits administrator whether the plan is self-insured (ERISA) or fully insured. Self-insured plans are governed by ERISA, which limits state insurance mandates.
3. Request a copy of your plan's medical policy for GLP-1 anti-obesity medications. Most plans post these on their provider portals, and members can request them directly.
4. Confirm your BMI and any comorbidities are documented in your primary care record within the past 12 months.

During Enrollment

• Ask Calibrate whether they submit physician visits to insurance as standalone E/M claims.
• Confirm the specialty pharmacy they use and verify that pharmacy is in-network for your plan's specialty drug benefit.
• Ask whether they submit labs to insurance or whether you need to have labs drawn at an in-network lab facility separately.

If You Are Denied

Request the specific clinical criteria cited in the denial letter. Most denial letters reference the plan's medical policy number. Pull that policy document and compare it line by line against your clinical documentation. Any criterion you meet that is not documented becomes a target for supplemental submission. (ACA Internal Appeals process, HealthCare.gov) (PMID 37127252)

If the internal appeal fails, file for an external review within 4 months of the final internal denial. External reviewers overturn internal denials in a meaningful percentage of cases, particularly when the clinical evidence is strong and the denial rests on a plan's non-coverage policy rather than a clinical necessity determination.

Cost If Insurance Does Not Cover the Medication

For members whose plans deny GLP-1 coverage, out-of-pocket costs for the medication itself are significant.

Wegovy's list price is approximately $1,349 per month for the 2.4 mg maintenance dose without insurance. Novo Nordisk offers a savings card that reduces cost to $25 per month for commercially insured patients who qualify (income and insurance status requirements apply). (Novo Nordisk Wegovy savings program, referenced via FDA drug information)

Zepbound's list price is approximately $1,059 per month for the 10 mg or 15 mg vials. Eli Lilly offers a savings program that may reduce cost for eligible commercially insured patients. Uninsured patients can access Zepbound single-dose vials through Lilly's direct-to-patient program at lower list prices than the auto-injector pen. (FDA Zepbound prescribing information)

Compounded semaglutide and tirzepatide remain available from 503A compounding pharmacies during FDA drug shortage designations, but neither Wegovy nor Zepbound appeared on the FDA drug shortage database as of early 2025, which means compounded versions occupy a legally uncertain space. (FDA 503A compounding guidance) Patients should discuss the regulatory status with their prescriber before choosing a compounded option.